Separovic L, Zhan Y, Kaweski SE, Sabaiduc S, Caraz. Interim estimates of vaccine effectiveness against influenza A(H1N1)pdm09 and A(H3N2) during a delayed influenza season, Canada, 2024/25. Euro Surveill. 2025 Jan;30(4)
The Canadian Sentinel Practitioner Surveillance Network (SPSN) reports interim 2024/25 vaccine effectiveness (VE) against acute respiratory illness due to laboratory-confirmed influenza during a delayed season of predominant A(H1N1)pdm09 and lower A(H3N2) co-circulation. Through mid-January, the risk of outpatient illness due to influenza A is reduced by about half among vaccinated vs unvaccinated individuals. Adjusted VE is 53% (95% CI: 36-65) against A(H1N1)pdm09, comprised of clades 5a.2a and 5a.2a.1, and 54% (95% CI: 29-70) against A(H3N2), virtually all clade 2a.3a.1.
See Also:
Latest articles in those days:
- High-throughput pseudovirus neutralisation maps the antigenic landscape of influenza A/H1N1 viruses 9 hours ago
- Timely vaccine strain selection and genomic surveillance improve evolutionary forecast accuracy of seasonal influenza A/H3N2 9 hours ago
- Evaluation of a Novel Data Source for National Influenza Surveillance: Influenza Hospitalization Data in the National Healthcare Safety Network, United States, September 2021-April 2024 9 hours ago
- Scenarios for pre-pandemic zoonotic influenza preparedness and response 9 hours ago
- Stability of Avian Influenza A(H5N1) Virus in Milk from Infected Cows and Virus-Spiked Milk 1 days ago
[Go Top] [Close Window]
